Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Regeneron Pharmaceuticals Inc (REGN) Financials: Revenue, Profit and Cash Flow
Regeneron Pharmaceuticals reported revenue of $14.34B for the fiscal year ended Dec 31, 2025, up 1.0% from the year before. That year, net income was $4.50B with a net margin of 31.4%, operating cash flow was $4.98B and free cash flow was $4.08B. The quarter ended Sep 30, 2026 had revenue of $5.12B and net income of $1.95B.
Revenue and Margins
The operating margin was 24.9% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $4.86B, a compound annual rate of 12.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $14.34B | +1.0% | 85.4% | 24.9% | 31.4% |
| Dec 2024 | $14.20B | +8.3% | 86.1% | 28.1% | 31.1% |
| Dec 2023 | $13.12B | +7.8% | 86.2% | 30.9% | 30.1% |
| Dec 2022 | $12.17B | -24.3% | 87.2% | 38.9% | 35.6% |
| Dec 2021 | $16.07B | +89.1% | 84.8% | 55.7% | 50.2% |
| Dec 2020 | $8.50B | +29.6% | 86.8% | 42.1% | 41.3% |
| Dec 2019 | $6.56B | +27.4% | 88.3% | 33.7% | 32.3% |
| Dec 2018 | $5.15B | -12.4% | 91.9% | 49.3% | 47.5% |
| Dec 2017 | $5.87B | +20.8% | 93.2% | 35.4% | 20.4% |
| Dec 2016 | $4.86B | N/A | 93.8% | 27.4% | 18.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 2.0% from the year before. In the quarter ended Sep 2026, net income rose 33.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B |
| Cost of revenue | $2.10B | $1.97B | $1.82B | $1.56B | $2.44B | $1.12B | $765.10M | $417.50M | $397.10M | $299.70M |
| Gross profit | $12.24B | $12.23B | $11.30B | $10.61B | $13.63B | $7.38B | $5.79B | $4.73B | $5.48B | $4.56B |
| Research and development | $5.97B | $5.23B | $4.63B | $3.85B | $2.91B | $2.73B | $2.45B | $1.47B | $2.08B | $2.05B |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.50M |
| EBITDA | $5.82B | $5.32B | $4.69B | $5.26B | $9.67B | $4.10B | $2.67B | $2.73B | $2.25B | $1.44B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.12B | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B |
| Gross profit | $4.54B | $3.71B | $2.94B | $3.30B | $3.23B | $3.15B | $2.56B | $3.22B | $3.23B | $3.07B | $2.71B | $2.92B |
| Operating income | $2.05B | $1.29B | $642.90M | $879.90M | $1.03B | $1.08B | $591.70M | $990.20M | $1.18B | $1.07B | $751.40M | $972.90M |
| Net income | $1.95B | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | $808.70M | $917.70M | $1.34B | $1.43B | $722.00M | $1.16B |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $2.02B by $1.09B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B |
| Current assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B |
| Cash and equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $812.70M | $535.20M |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B |
| Short-term debt | $37.80M | N/A | N/A | $720.00M | $719.70M | $1.63B | N/A | $90.80M | $468.83M | $129.56M |
| Long-term debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $0 | N/A | $703.45M | $351.57M |
| Shareholder equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $44.41B | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | $33.08B |
| Total liabilities | $10.91B | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B | $7.38B | $7.11B |
| Cash and equivalents | $3.66B | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B | $2.60B | $2.73B |
| Shareholder equity | $33.50B | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B | $26.99B | $25.97B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 81.9% of operating cash flow. Dividends and share repurchases together came to 93.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B |
| Capital expenditures | $898.40M | $755.90M | $718.60M | $590.10M | $551.90M | $614.60M | $429.60M | $383.10M | $272.60M | $511.90M |
| Free cash flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $974.00M |
| Dividends paid | $370.30M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | $358.69M | $500.18M |
| Share repurchases | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $275.90M | $4.40M | $0 | $643.40M |
| Investing cash flow | -$629.10M | -$2.47B | -$3.19B | -$3.78B | -$5.38B | -$70.60M | -$2.03B | -$1.46B | -$1.01B | -$1.05B |
| Financing cash flow | -$3.72B | -$2.20B | -$1.79B | -$1.01B | -$1.01B | -$1.97B | -$252.10M | -$77.10M | -$24.40M | -$700.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.78B | $813.00M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354.00M | $1.51B | $1.09B |
| Capital expenditures | $300.20M | $240.20M | $230.60M | $248.70M | $201.40M | $219.00M | $229.30M | $199.60M | $241.90M | $180.50M | $133.90M | $251.40M |
| Free cash flow | $1.48B | $572.80M | $848.30M | $922.00M | $1.42B | $925.40M | $815.80M | $1.06B | $1.05B | $173.50M | $1.38B | $838.30M |
Frequently Asked Questions About REGN
What is Regeneron Pharmaceuticals' annual revenue?
Regeneron Pharmaceuticals reported revenue of $14.34B for the fiscal year ended Dec 31, 2025.
How fast is Regeneron Pharmaceuticals' revenue growing?
Revenue was up 1.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.6%.
Is Regeneron Pharmaceuticals profitable?
Yes. Regeneron Pharmaceuticals reported net income of $4.50B for the fiscal year ended Dec 31, 2025, with a net margin of 31.4%.
How much free cash flow does REGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $4.98B minus capital expenditures of $898.40M produced free cash flow of $4.08B.
How much debt does Regeneron Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.99B, short-term debt of $37.80M and cash and equivalents of $3.12B.
REGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts